VivoSim Labs, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.1M
- Price
- $0.3225
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.71%
- Volume
- 1.5M
About
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Quick stats
Shares outstanding3.5M
Computed float3.1M
Float / shares88.9%
Cash runway (months)2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001497253
Websitehttps://vivosim.ai
AI Summary
AI-generated1/6
majormixedother
VivoSim Provides Financial and Listing Compliance Update
VivoSim regained compliance with Nasdaq Listing Rule 5550(b)(1) after boosting stockholders' equity above the $2.5M minimum requirement.
The company's cash position strengthened to approximately $10.1 million as of August 3, supported by a $5 million milestone payment from Eli Lilly, $1 million from escrow, and a $4 million financing via warrants priced at $0.85.
To meet compliance, the company underwent significant dilution, with outstanding shares rising from roughly 3.2 million to 13.4 million between June 30 and August 3, yet management reiterated guidance for 500%+ revenue growth in Fiscal Year 2027.
Red flags
- Outstanding shares increased by over 300% in one month due to warrant exercises
- Financing proceeds largely used for general corporate purposes/compliance